145 related articles for article (PubMed ID: 10877374)
1. Incidence of brimonidine allergy in patients previously allergic to apraclonidine.
Williams GC; Orengo-Nania S; Gross RL
J Glaucoma; 2000 Jun; 9(3):235-8. PubMed ID: 10877374
[TBL] [Abstract][Full Text] [Related]
2. Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy.
Gordon RN; Liebmann JM; Greenfield DS; Lama P; Ritch R
Eye (Lond); 1998; 12 ( Pt 4)():697-700. PubMed ID: 9850267
[TBL] [Abstract][Full Text] [Related]
3. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
Shin DH; Glover BK; Cha SC; Kim YY; Kim C; Nguyen KD
Am J Ophthalmol; 1999 May; 127(5):511-5. PubMed ID: 10334342
[TBL] [Abstract][Full Text] [Related]
4. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264
[TBL] [Abstract][Full Text] [Related]
5. Allergic reactions to brimonidine in patients treated for glaucoma.
Blondeau P; Rousseau JA
Can J Ophthalmol; 2002 Feb; 37(1):21-6. PubMed ID: 11865954
[TBL] [Abstract][Full Text] [Related]
6. Clonidine provides an allergy-free alternative in glaucoma patients with proven allergy to apraclonidine.
Geyer O; Schmidt KG; Pianka P; Neudorfer M; Lazar M
Graefes Arch Clin Exp Ophthalmol; 2000 Feb; 238(2):149-52. PubMed ID: 10766284
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions.
Butler P; Mannschreck M; Lin S; Hwang I; Alvarado J
Arch Ophthalmol; 1995 Mar; 113(3):293-6. PubMed ID: 7887842
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
[TBL] [Abstract][Full Text] [Related]
9. Update in glaucoma: the new pharmacotherapies. Brimonidine versus apraclonidine.
Crichton AC
Can J Ophthalmol; 1998 Aug; 33(5):254-5; discussion 257-8. PubMed ID: 9740952
[No Abstract] [Full Text] [Related]
10. Exposure to topical apraclonidine in children with glaucoma.
Wright TM; Freedman SF
J Glaucoma; 2009; 18(5):395-8. PubMed ID: 19525731
[TBL] [Abstract][Full Text] [Related]
11. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery.
Chen TC
J Cataract Refract Surg; 2005 Sep; 31(9):1707-12. PubMed ID: 16246772
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans.
Schadlu R; Maus TL; Nau CB; Brubaker RF
Arch Ophthalmol; 1998 Nov; 116(11):1441-4. PubMed ID: 9823343
[TBL] [Abstract][Full Text] [Related]
13. High incidence of topical allergic reactions to 1% apraclonidine.
Feibel RM
Arch Ophthalmol; 1995 Dec; 113(12):1579-80. PubMed ID: 7487638
[No Abstract] [Full Text] [Related]
14. Delayed hypersensitivity to brimonidine tartrate 0.2% associated with high intraocular pressure.
Watts P; Hawksworth N
Eye (Lond); 2002 Mar; 16(2):132-5. PubMed ID: 11988811
[TBL] [Abstract][Full Text] [Related]
15. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A
J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302
[TBL] [Abstract][Full Text] [Related]
16. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery.
Chen TC; Ang RT; Grosskreutz CL; Pasquale LR; Fan JT
Ophthalmology; 2001 Jun; 108(6):1033-8. PubMed ID: 11382625
[TBL] [Abstract][Full Text] [Related]
17. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.
Sullivan-Mee M; Pensyl D; Alldredge B; Halverson K; Gerhardt G; Qualls C
J Ocul Pharmacol Ther; 2010 Aug; 26(4):355-60. PubMed ID: 20653479
[TBL] [Abstract][Full Text] [Related]
18. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
Chevrier RL; Assalian A; Duperré J; Lesk MR
Ophthalmic Surg Lasers; 1999 Mar; 30(3):199-204. PubMed ID: 10100253
[TBL] [Abstract][Full Text] [Related]
19. Allergic contact dermatitis from apraclonidine in eyedrops.
Silvestre JF; Carnero L; Ramón R; Albares MP; Botella R
Contact Dermatitis; 2001 Oct; 45(4):251. PubMed ID: 11683848
[No Abstract] [Full Text] [Related]
20. Prophylactic brimonidine before LASIK.
Uretmen O; Ates H; Andaç K
J Refract Surg; 2003; 19(5):612. PubMed ID: 14518756
[No Abstract] [Full Text] [Related]
[Next] [New Search]
